Please login to the form below

Not currently logged in
Email:
Password:

SuperGen and Astex to merge

Cancer specialists SuperGen and Astex Therapeutics have agreed to merge

Oncology specialists, US-based SuperGen, and Astex Therapeutics, a privately held UK firm, have agreed to merge.

The combined entity, to be named Astex Pharmaceuticals, is expected to be listed on NASDAQ under the symbol ASTX.

It plans to leverage a revenue stream from its product Dacogen, marketed in North America by Eisai and in the rest of the world by Johnson & Johnson. The combined company's clinical pipeline will include seven drugs in development – four of which are currently in or entering into phase II clinical trials and three of which are partnered with large pharmaceutical companies.

James S J Manuso, chairman, president and CEO of SuperGen, will become chairman and CEO of Astex Pharmaceuticals. Harren Jhoti, CEO of Astex Therapeutics, will become president and a member of the board of directors of the new company.

Manuso said: "We believe the combination of SuperGen and Astex accelerates SuperGen's business model and brings together the people, partnerships, clinical assets, discovery platforms, infrastructures and capital resources to generate significant shareholder value in the years ahead.

"The outstanding pipeline and highly regarded drug discovery platform of Astex, coupled with the product candidates, development expertise and capital resources of SuperGen, are expected to give rise to a powerful new entity capable of delivering valuable cancer therapies targeting critical medical needs."

The deal, which is subject to regulatory and shareholder approvals, is expected to close in July 2011.

7th April 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics